# Evaluating the Safety and Efficacy of SB Injection in Patients With Advanced or Primary Hepatocellular Carcinoma (HCC)

> **NCT01308645** · PHASE2 · UNKNOWN · sponsor: **SBPharmaceutical IND, Co., LTD** · enrollment: 30 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** SB injection

## Key facts

- **NCT ID:** NCT01308645
- **Lead sponsor:** SBPharmaceutical IND, Co., LTD
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2010-12
- **Primary completion:** 2011-12
- **Final completion:** 2012-03
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2011-06-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01308645

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01308645, "Evaluating the Safety and Efficacy of SB Injection in Patients With Advanced or Primary Hepatocellular Carcinoma (HCC)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01308645. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*